Estimaciones de analistas de Wall Street para INmune Bio, Inc. (INMB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 6 |
| Mantener | 2 |
| Venta | 1 |
| Venta fuerte | 0 |
| Analistas totales | 9 |
| Calificación media (1-5) | 0.56 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-29 | $-0.15 | ||
| 2026-08-06 | $-0.05 | $-0.21 | +75.8% |
| 2026-05-07 | $-0.20 | $-0.24 | +18.4% |
| 2026-03-30 | $-0.18 | $-0.27 | +33.3% |
| 2025-10-30 | $-0.24 | $-0.31 | +22.6% |
| 2025-08-07 | $-1.05 | $-0.37 | -183.8% |
| 2025-05-08 | $-0.43 | $-0.43 | +0.0% |
| 2025-03-27 | $-0.40 | $-0.54 | +25.9% |
Ratios de valoración
| Precio / Valor contable | 2.69 |
| EV / EBITDA | -2.63 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $11000 | $181000 | $374000 | $155000 | $14000 | $50000 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | $11000 | $181000 | $374000 | $155000 | $14000 | $50000 |
| I+D | $101495 | $435362 | $1.1M | $3.3M | $5.9M | $20.5M | $17.1M | $20.3M | $33.2M | $20.7M |
| Generales y Administrativos | $125996 | $546118 | $9.1M | $4.5M | $6.3M | $8.8M | $9.3M | $9.6M | $9.5M | $10.3M |
| Gastos Operativos | $227491 | $981480 | $12.4M | $7.8M | $12.2M | $29.3M | $26.3M | $29.9M | $42.6M | $30.9M |
| Beneficio Operativo | -$227000 | -$981000 | -$12.4M | -$7.8M | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$30.9M |
| EBITDA | -$50000 | $149990 | 0 | -$7.7M | 0 | -$1.2M | -$1.3M | -$267000 | -$41.5M | -$45.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$277000 | -$831000 | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$277000 | -$831000 | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| BPA | $-0.05 | $-0.07 | $-1.11 | $-0.89 | $-1.01 | $-1.88 | $-1.52 | $-1.67 | $-2.11 | $-1.86 |
| BPA Diluido | $-0.05 | $-0.07 | $-1.11 | $-0.89 | $-1.01 | $-1.88 | $-1.52 | $-1.67 | $-2.11 | $-1.86 |
| Acciones en Circulación (Diluidas) | $5.1M | $11.2M | $11.2M | $10.3M | $12.0M | $16.1M | $17.9M | $18.0M | $19.9M | $26.6M |
Precio
| Precio | $2.05 |
| Capitalización | $54M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ALGS · BRNS · CVM · FGEN · MRSN · OKUR · PDSB
Explorar sector: Healthcare · Biotechnology
Más secciones de INMB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones